Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/120960
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Niclosamide reduces glucagon sensitivity via hepatic PKA inhibition in obese mice: implications for glucose metabolism improvements in type 2 diabetes
Author: Chowdhury, M.
Turner, N.
Bentley, N.
Das, A.
Wu, L.
Richani, D.
Bustamante, S.
Gilchrist, R.
Morris, M.
Shepherd, P.
Smith, G.
Citation: Scientific Reports, 2017; 7(1):40159-1-40159-9
Publisher: Springer Nature
Issue Date: 2017
ISSN: 2045-2322
2045-2322
Statement of
Responsibility: 
Md. Kamrul Hasan Chowdhury, Nigel Turner, Nicholas L. Bentley, Abhirup Das, Lindsay E. Wu, Dulama Richani, Sonia Bustamante, Robert B. Gilchrist, Margaret J. Morris, Peter R. Shepherd, Greg C. Smith
Abstract: Type 2 diabetes (T2D) is a global pandemic. Currently, the drugs used to treat T2D improve hyperglycemic symptom of the disease but the underlying mechanism causing the high blood glucose levels have not been fully resolved. Recently published data showed that salt form of niclosamide improved glucose metabolism in high fat fed mice via mitochondrial uncoupling. However, based on our previous work we hypothesised that niclosamide might also improve glucose metabolism via inhibition of the glucagon signalling in liver in vivo. In this study, mice were fed either a chow or high fat diet containing two different formulations of niclosamide (niclosamide ethanolamine salt - NENS or niclosamide - Nic) for 10 weeks. We identified both forms of niclosamide significantly improved whole body glucose metabolism without altering total body weight or body composition, energy expenditure or insulin secretion or sensitivity. Our study provides evidence that inhibition of the glucagon signalling pathway contributes to the beneficial effects of niclosamide (NENS or Nic) on whole body glucose metabolism. In conclusion, our results suggest that the niclosamide could be a useful adjunctive therapeutic strategy to treat T2D, as hepatic glucose output is elevated in people with T2D and current drugs do not redress this adequately.
Keywords: Glucose metabolism; type 2 diabetes
Rights: © The Author(s) 2017. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
DOI: 10.1038/srep40159
Grant ID: ARC
Appears in Collections:Aurora harvest 4
Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_120960.pdfPublished Version1.36 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.